These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30286103)

  • 1. Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.
    Schifano F; Chiappini S
    PLoS One; 2018; 13(10):e0204443. PubMed ID: 30286103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Int J Neuropsychopharmacol; 2019 Apr; 22(4):270-277. PubMed ID: 30722037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.
    Chiappini S; Schifano F
    J Clin Psychopharmacol; 2018 Feb; 38(1):72-79. PubMed ID: 29210868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loperamide Trends in Abuse and Misuse Over 13 Years: 2002-2015.
    Lasoff DR; Koh CH; Corbett B; Minns AB; Cantrell FL
    Pharmacotherapy; 2017 Feb; 37(2):249-253. PubMed ID: 27995643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-2 Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports.
    Milano G; Chiappini S; Mattioli F; Martelli A; Schifano F
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):182-187. PubMed ID: 29498199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
    Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
    J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intentional Misuse and Abuse of Loperamide: A New Look at a Drug with "Low Abuse Potential".
    Borron SW; Watts SH; Tull J; Baeza S; Diebold S; Barrow A
    J Emerg Med; 2017 Jul; 53(1):73-84. PubMed ID: 28501383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loperamide misuse and abuse.
    Miller H; Panahi L; Tapia D; Tran A; Bowman JD
    J Am Pharm Assoc (2003); 2017; 57(2S):S45-S50. PubMed ID: 28189538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk.
    Lee VR; Vera A; Alexander A; Ruck B; Nelson LS; Wax P; Campleman S; Brent J; Calello DP
    Clin Toxicol (Phila); 2019 Mar; 57(3):175-180. PubMed ID: 30585509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.
    Chiappini S; Schifano F; Corkery JM; Guirguis A
    J Psychopharmacol; 2021 Jun; 35(6):681-692. PubMed ID: 33427017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database.
    Chiappini S; Schifano F; Corkery JM; Guirguis A
    Brain Sci; 2020 Feb; 10(2):. PubMed ID: 32079135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loperamide abuse cardiotoxicity. Should loperamide still be an over the counter medication?
    Idris A; Mihora DC; Kaye K
    Am J Emerg Med; 2018 Sep; 36(9):1716.e1-1716.e3. PubMed ID: 29779679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
    Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Schifano F
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Front Pharmacol; 2019; 10():46. PubMed ID: 30774595
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA to Minimize Abuse Potential of OTC Antidiarrheal.
    Aschenbrenner DS
    Am J Nurs; 2018 Jun; 118(6):25-26. PubMed ID: 29794917
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).
    Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Harris DR; Schifano F
    Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic Trends in Loperamide Abuse and Misuse.
    Vakkalanka JP; Charlton NP; Holstege CP
    Ann Emerg Med; 2017 Jan; 69(1):73-78. PubMed ID: 27823872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database.
    Carnovale C; Mahzar F; Scibelli S; Gentili M; Arzenton E; Moretti U; Leoni O; Pozzi M; Peeters GGAM; Clementi E; Medaglia M; Radice S
    Eur J Pediatr; 2019 Feb; 178(2):161-172. PubMed ID: 30374752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loperamide, the "Poor Man's Methadone": Brief Review.
    Stanciu CN; Gnanasegaram SA
    J Psychoactive Drugs; 2017; 49(1):18-21. PubMed ID: 27918873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.